Endocrine testing market - Worldwide Market Shares, Strategies, and Forecasts 2015 to 2023

The endocrine system is made up of several glands such as pineal, pituitary, and thyroid and secretory organs such as hypothalamus and pancreas. These glands secrete hormones such as luteinizing hormone (LH), insulin, follicle stimulating hormone (FSH), and estradiol directly into the blood stream for the proper regulation of a number of bodily functions such as growth and homeostasis. Endocrine testing is done on biological samples to regulate the levels of endocrine hormones and to detect any deviation in hormone production. Less secretion (hyposecretion) or excess secretion (hypersecretion) can lead to a number of endocrine disorders such as menopause, infertility, and thyroid dysfunction.

Business intelligence firm Transparency Market Research, in a recent publication, states that the global endocrine testing market is anticipated to expand at a healthy CAGR of 8.50% from 2015 to 2023, rising from a value of US$6.1 bn in 2014 to US$12.8 bn in 2023.

Breakthrough Made by Scientists at Glasgow University Could Mean Better Endocrine Testing

A major discovery made by a team of researchers in the United Kingdom is believed to have the potential for improved endocrine testing and the testing and treatment of pancreatic cancer. According to the American Cancer Society, pancreatic cancer is one of the biggest health concerns in America, with over 48,000 Americans diagnosed with the disease last year.

Scientists at the University of Glasgow have discovered that pancreatic cancer is actually four separate diseases and each one requires different diagnoses and therapies. The scientists found that there are four primary genetic errors – classified as pancreatic progenitor, squamous-type, aberrantly differentiated endocrine exocrine, and immunogenic – that have resulted in the growth of tumors in the 456 patients studied in the experiment. The discovery of these errors, researchers believe, will be able to help speed up efforts in the development of newer forms of pancreatic cancer treatment.

Request a Sample of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1645

Adoption of Tele-health Services to Fuel the Growth of Global Endocrine Testing Market

By type, the global endocrine testing market can be categorized into thyroid stimulating hormone (TSH) test, human chorionic gonadotropin (HCG) test, dehydroepiandrosterone sulfate (DHEAS) test, testosterone test, progesterone test, prolactin test, estradiol (E2) test, insulin test, follicle stimulating hormone (FSH) test, cortisol test, luteinizing hormone (LH) test, and others (such as thymosin, gastrin, secretin). The thyroid stimulating hormone (TSH) segment accounts for the highest share in the overall endocrine testing market, whereas insulin testing is expected to grow at a fast pace in the coming years. By technology, the global endocrine testing market can be classified into sensor, immunoassay, monoclonal and polyclonal antibody, clinical chemistry technologies, tandem mass spectrometry, and others. In 2014, the immunoassay technologies segment led the overall endocrine testing market, whereas the tandem mass spectrometry segment is projected to grow rapidly in the next few years.

By end use, the global market for endocrine testing can be segmented into home-based tests, ambulatory care centers, hospitals, physician offices, and commercial laboratories. Among these segments, commercial laboratories hold the biggest market share in the global endocrine testing market due to the presence of skilled and dedicated laboratory personnel, increased use of specialized diagnostics tools, and swift diagnostics facilities, which is propelling the global endocrine market. The introduction of tele-health services is one of the major factors projected to fuel the commercial laboratories segment in the coming years. On the other hand, the home-based tests segment is expected to register the highest growth in the next few years, owing to easy operation and the instant result of the test kits.

Endocrine Testing Market: Oligopolistic Nature of Competitive Landscape

 By nature, the competitive landscape of the global endocrine testing market is immensely oligopolistic with the top five vendors making up a whopping 90% of the overall market. In 2014, F-Hoffman La Roche Ltd. dominated the scene with a share of 23.10% in the global market, driven by increased market penetration and a wide product portfolio. Abbott Laboratories came in second with a share of 19.30% in 2014, fueled by a broad range of technological platforms. DiaSorin, Agilent Technologies, and Siemens Healthcare followed next with a share of 16.80%, 15.40%, and 13.80% respectively. These companies are propelled by the presence of a broad array of endocrine testing technologies and products. Accounting for a combined share of 11.60% in the overall revenue in 2014 were players such as Bio Rad Laboratories, AB SCIEX LLC, Sysmex Corporation, Lab Corporation, Quest Diagnostics, Biomedical Diagnostics, Ortho-clinical Diagnostics, Thermo Fisher Scientific, and bioMerieux.